A phase II study of timdarpacept—a SIRPα-Fc fusion protein—combined with azacitidine reported an overall response rate of 72.7% in 24 Chinese patients with higher-risk chronic myelomonocytic leukemia (CMML). The regimen was tested as first-line therapy. The results target a major challenge in CMML: durable disease control remains difficult with existing approaches, and combination strategies that modulate myeloid signaling are gaining attention. The snippet does not specify complete response versus partial response distribution or median durability, but the high reported ORR is likely to influence next-step discussions. For biotech decision-makers, the key near-term issue is how response durability and safety evolve as the program scales beyond a small cohort and expands into larger confirmatory studies. —